# {{title}}

**Product:** {{product}} • **Sponsor:** {{sponsor}}

## 1. Bioanalytical Methods & Interference
- Standard bridging ADA shows drug-dependent masking at therapeutic levels.
- PandA (PEG + Acid) increases drug tolerance (≥80% recovery to ≥{{required_tol}} µg/mL).

![Drug tolerance](output/figures/recovery_overlay_sim_vs_lit.png)

PASS/ALERT summary:
![PASS/ALERT](output/figures/pass_alert_table.png)

## 2. Population PK & Variability (brief)
- ADA positivity associates with reduced troughs at Week 52.
![ADA vs exposure](output/figures/wk52_by_detected_ADA_assay.png)

## 3. Exposure–Response & Target Attainment
- True E–R trend shows reduced efficacy at low troughs.
![True E–R](output/figures/exposure_response_true.png)

Target attainment (percentage above threshold), by assay:
`output/TLG_target_attainment.csv`

## 4. Dose Recommendation
- Given reduced exposure in ADA+ under standard detection, use **PandA-based immunogenicity** for PK/E–R decisions.
- If clinical goal requires ≥X% target attainment, consider dose adjustment **only if** safety margin allows (placeholder language).

## 5. Conclusions
- Standard assay fails tolerance benchmark; PandA passes.
- Use PandA for confirmatory ADA detection at therapeutic drug levels.
